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Abstract
Background: Given that treatments for chronic lymphocytic leukaemia (CLL) are palliative rather than curative, 
evaluating the patient-perceived impacts of therapy is critical. To date, no utility (preference) studies from the general 
public or patient perspective have been conducted in CLL. The objective of this study was to measure preferences for 
health states associated with CLL treatment.
Methods: This was a cross-sectional study of 89 members of the general population in the UK (England and Scotland). 
Using standard gamble, each participant valued four health states describing response status, six describing treatment-
related toxicities based on Common Toxicity Criteria, and two describing line of treatment. The health states 
incorporated standardized descriptions of treatment response (symptoms have "improved," "stabilized," or "gotten 
worse"), swollen glands, impact on daily activities, fatigue, appetite, and night sweats. Utility estimates ranged from 0.0, 
reflecting dead, to 1.0, reflecting full health.
Results: Complete response (CR) was the most preferred health state (mean utility, 0.91), followed by partial response 
(PR), 0.84; no change (NC), 0.78; and progressive disease (PD), 0.68. Among the toxicity states, grade I/II nausea and 
nausea/vomiting had the smallest utility decrements (both were -0.05), and grade III/IV pneumonia had the greatest 
decrement (-0.20). The utility decrements obtained for toxicity states can be subtracted from utilities for CR, PR, NC, and 
PD, as appropriate. The utilities for second- and third-line treatments, which are attempted when symptoms worsen, 
were 0.71 and 0.65, respectively. No significant differences in utilities were observed by age, sex, or knowledge/
experience with leukaemia.
Conclusions: This study reports UK population utilities for a universal set of CLL health states that incorporate 
intended treatment response and unintended toxicities. These utilities can be applied in future cost-effectiveness 
analyses of CLL treatment.
Background
Chronic lymphocytic leukaemia (CLL) is a progressive
form of leukaemia characterised by an accumulation of
abnormal lymphocytes that have lost the ability to
undergo apoptosis (programmed cell death). These lym-
phocytes accumulate in the lymph nodes, liver, spleen,
blood, and bone marrow and compromise the activity of
cell mediated and humoral immunity with loss of
immune memory. Consequently, patients with CLL typi-
cally experience recurrent infections, some of which can
be serious [1]. CLL predominantly is a disease among
older individuals, with a median age at diagnosis of 72
years [2]. Patient age, however, does not appear to influ-
ence the presence of symptoms, with no difference in
clinical findings found between younger (<55) and older
patient populations [1]. CLL is approximately twice as
common in men as in women, and it is the most common
form of leukaemia in W estern na tions, with an annual
incidence of 3 to 3.5 cases per 100,000 [2].
With the exception of blood and marrow transplanta-
tion, CLL is an inherently incurable condition and treat-
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ments are therefore focused on controlling symptoms
a n d  o p t i m i s i n g  h e a l t h - r e l a t e d  q u a l i t y  o f  l i f e  [ 3 ] .  T h u s ,
quantifying the patient-perceived impact of therapy is a
critical outcome in CLL research. Health status utility
assessments enable quantification of preferences for
selected health outcomes and, consequently, estimation
of quality-adjusted life years (QALYs). Health technology
assessment (HTA) agencies established by regulatory
authorities in various countries such as the United King-
dom, Australia, and Canada emphasize the importance of
QALYs in product evaluation. For example, a briefing
paper disseminated by the National Institute for Health
and Clinical Excellence (NICE) cites that health state util-
ity values are a key parameter in cost-effectiveness mod-
els and have been found to have a major impact on the
results of many appraisals [4]. As the Scottish Medicines
Consortium (SMC) states, they have a preference for
cost-utility analyses using QALYs as the primary outcome
measure in order to make clear comparisons of the value
of new medicines [5]. QALYs are particularly useful for
conditions for which treatment is not curative but pallia-
tive, such as cancer. For example, the incremental cost
per QALY gained was a key endpoint in recent cost-effec-
tiveness evaluations in CLL and chronic myeloid leukae-
mia (CML) [6-8].
To date, no utility studies from the patient or general
population perspective have been conducted in CLL
[9,10]. While one clinician group, the Wessex Develop-
ment and Evaluation Committee (1995), attempted to
estimate utility weights for select CLL health states by
gauging where patients might be on the Index of Health-
related Quality of Life (IHQOL) measure, researchers
have since recommended caution in using utilities based
on such simplistic methodology [11,12]. Thus, there is an
unmet need for a de novo utility study in CLL.
HTA agencies generally prefer that generic measures
such as the EQ-5D are used to estimate utilities incorpo-
rated into cost-effectiveness evaluations [4]. However,
generic measures, as opposed to disease-specific utility
measures, may not adequately capture key psychological
impacts associated with CLL treatment, for example, the
impact of knowing that one is responding to treatment.
This knowledge, and the resulting hopefulness that may
result, can have substantial impact on a patient's outlook
and psychological health. For example, in a qualitative
study of patients with chronic leukaemia that investigated
how these patients conceptualise quality of life, hope was
identified as a key theme associated with coping [13].
Little work in the area of preference-based utilities has
been conducted that captures both the intended clinical
response and unintended toxicities associated with treat-
ment. Measurement of preferences for health states char-
acterizing cancer-specific states associated with
treatment can be particularly valuable in order to help cli-
nicians and decision-makers better understand the bal-
ance between the physiological and psychological
benefits of treatment versus the negative impact of these
treatments on daily life [14]. The purpose of the current
study was to use a vignette-based utility approach to
measure preferences for standardized health states that
include clinical response and toxicities observed during
treatment of CLL.
Methods
A cross-sectional study was performed to elicit utilities
for CLL health states among, as suggested by the UK
National Institute for Health and Clinical Excellence,
members of the general public [4]. Four trained inter-
viewers used the standard gamble technique, the only
utility technique consistent with the axioms of utility the-
ory, which involves making decisions under conditions of
uncertainty [15]. Respondents imagine that they are in a
selected health state. They can remain in that state, or
take a gamble that involves a chance (p) of achieving full
health with a corresponding chance (1-p) of being dead.
The  p  probabilities are varied using a ping-pong
approach until the respondent is indifferent between the
two options. The interviewer used a chance board with a
probability wheel using 2-color pie charts to illustrate the
different probabilities.
Study participants were recruited from the general
population in the UK, including both England and Scot-
land, in March 2009. Each interviewer recruited 15-25
laypeople in the U.K. (England and Scotland) through
word-of-mouth as well as through a panel of laypeople
who had previously volunteered to be participants for
research studies. Eligible participants were residents of
England or Scotland, aged 18 or over, and capable of giv-
ing informed consent. The interviews were conducted in-
person, and the participants completed a demographic
questionnaire and, prior to beginning the standard gam-
ble exercise, they were asked to order the health states
from most preferable to least preferable. All participants
provided informed consent and received compensation
of 25GBP for their time. This study was approved by the
Independent Investigational Review Board (Plantation,
FL) and complied with the tenets of the Declaration of
Helsinki.
Health State Development
The health states were designed to describe the func-
tional and patient-centred impacts of CLL and it treat-
ment, rather than clinical descriptions of the disease, in
line with published guidelines for health state develop-
ment [15]. Development was an iterative process that
involved incorporating input from the literature, patient
web-based discussion forums, physicians with expertise
in CLL, and patients with CLL.Beusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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The following domains were described, enabling bal-
anced descriptions across the health states: cancer
description, "cancer of the blood"; treatment response
category; swollen glands in neck, armpits, or groin; limi-
tations in performing daily activities; level of fatigue;
appetite; and trouble sleeping because of night sweats.
These domains are those that previous researchers have
identified as important in CLL. In a review of the burden
and outcomes associated with leukaemia, for example,
Redaelli  et al [ 1 6 ]  r e p o r t e d  t h a t  p h y s i c a l  f u n c t i o n i n g ,
role-functioning, and fatigue/energy levels were among
the most important domains related to CLL. With regard
to symptoms, Kermani et al [17] found that, in CLL
patients, fatigue was the most common (present in 54% of
patients), followed by dyspnoea (32%), abdominal pain
(29%), and weight loss (22%). In addition, lymphadenopa-
thy (enlarged lymph nodes in the groin, spleen, or neck)
was observed in 89% of patients. Other researchers
[18,19] also have reported that, compared to population
norms, CLL patients have more complaints about fatigue,
appetite loss, and sleep disturbances. Based on patient
posts on the web-based CLL forums, frequent and both-
ersome impacts of CLL were related to fatigue/energy
levels, ability to perform daily activities, appetite distur-
bances, sleep disturbances, and noticeably enlarged
lymph nodes.
In all, four CLL treatment-related response states, six
toxicity-related health states, and two health states
r e f l e c t i n g  t h e  i m p a c t  o f  u n d e r g o i n g  a  s e c o n d  o r  t h i r d
course of treatment were developed (health states located
in Additional File 1). The domains describing clinical
response status were based on the National Cancer Insti-
tute Working Group (NCIWG)'s treatment response def-
initions for CLL [20]. The complete response state was
based on the complete absence of symptoms; partial
response represented a ≥ 50% reduction in symptoms; no
change meant that the disease was stable (i.e., symptoms
not worsening or improving); and progressive disease
indicated that symptoms were worsening.
With respect to the toxicity states, these were identified
based on common toxicities experienced with bendamus-
tine and chlorambucil, and draft descriptions were devel-
oped using the Cancer Therapy Evaluation program's
Common Terminology Criteria version 3.0 [21]. Because
it would be too cumbersome for respondents to value all
possible combinations of clinical response status with the
various possible toxicities, the toxicity health states
described each toxicity in association with the base
health state of no change ( N C )  h e a l t h  s t a t e .  N C  w a s
selected to pair with the toxicities as opposed to PR given
that this is a more conservative approach; if the toxicities
were coupled with PR, for example, it is possible that
respondents would not rate them as poorly as they would
if they were coupled with NC because they may be more
accepting of an aggressive therapy if they know that the
treatment is working.
The draft health states were refined after iterative
review by four independent clinicians. Draft health states
w e r e  t e s t e d  i n  f i v e  S c o t t i s h  C L L  p a t i e n t s  r e c r u i t e d
through the CLL Support Association, a web-based sup-
port group based in the UK, and final revisions were
made based on their feedback. The states were developed
to be easily comprehensible from the general public's per-
spective and gender-neutral. During the interview, the
health states were labelled using symbols, as opposed to
numerical identifiers, to avoid imposing any hierarchical
order among them.
Statistical Analysis
This study was designed to collect data from 93 people;
this was not determined or based on a formal power anal-
ysis because there was no specific hypothesis to test.
Demographic data were summarised by means and stan-
dard deviations for continuous variables, and proportions
for categorical variables. Means were calculated for the
rank orderings of the health states. For each health state,
the respective standard gamble utility equalled the proba-
bility p of full health at the point where the respondent
was indifferent between staying in the health state and
taking the gamble. Utility scores range from 0.0, reflect-
ing being dead, to 1.0, reflecting full health. A decision
rule was implemented for eliminating illogical responses.
Specifically, participants who had at least three illogical
responses (e.g., valuing no change plus a toxicity as higher
than no change) were eliminated from all analyses. Utili-
ties were summarized using means, standard deviations,
medians, 95% confidence intervals (95% CI), and stan-
dard errors (SE). Utility decrements for toxicities were
generated by subtracting the utility for the base case (no
change) from the utility of the toxicity state (each of
which was described in association with no change).
Although the study was not powered to test for differ-
ences in utilities between subgroups, exploratory analyses
were made comparing utilities by region (England vs.
Scotland), age group, sex, and whether or not the respon-
dents were knowledgeable about leukaemia using the
Student's t-test. All statistical analyses were conducted
using SAS v9.0.
Results
In total, 93 respondents were recruited from the UK,
including 62 from England and 31 from Scotland. Of
these, four respondents (4.5%) provided at least three
illogical responses (utility weights were higher for a less
favourable health state versus a more favourable health
state), and they were excluded from the analysis. Thus, 89
participants, 59 from England and 30 from Scotland,
were included in the final analysis. In comparison to theBeusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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demographic distributions of the target adult populations
in Scotland and in England & Wales based on the 2001
UK census [22], fewer individuals in the study sample
were from ages 18-24 (8% vs. 14%) and more had qualifi-
cations or achieved greater than Level 1 education (80%
vs. 71%). Mean respondent age was 47 ± 16 years, and
44% were male. The respondents represented five cities in
Scotland and nine cities in England.
As expected, full health and complete response had the
first and second highest mean rankings, respectively,
among the health states, followed by partial response and
no change, respectively. The grade 1/2 toxicity health
states were ranked higher than the grade 3/4 toxicity
health states, and no change plus grade 3/4 pneumonia
was ranked the worst.
Table 1 reports the standard gamble utility values for
the CLL health states for the total sample. As expected,
among the clinical response states, complete response was
most preferred (utility = 0.91), followed by partial
response (utility = 0.84), followed by no change (utility =
0.78) and progressive disease (utility = 0.68), respectively.
The number of treatment attempts required in CLL (first,
second, or third-line therapy) was associated with differ-
ent utility weights. Specifically, the utility for second-line
therapy (0.71) was lower than that found for no change (0.
78), and the utility for third-line treatment was lower than
that of progressive disease (0.68).
The health states that comprised no change plus toxici-
ties were less preferred than the no change base state, and
the no change plus grade 3/4 (more severe) toxicity health
states had lower utilities than the no change plus grade 1/
2 (less severe) toxicity health states. Of all of the health
states, no change plus grade 3/4 pneumonia was the least
preferred (utility = 0.58). Table 1 reports the respective
utility decrements associated with each toxicity state.
These can be added to those values for the complete
response, partial response,  progressive disease, and no
change, as applicable.
A comparison of utility data between England and
Scotland showed that utility weights reported by Scottish
respondents were higher than those reported by English
participants for most of the health states (Table 2). Nev-
ertheless, the relative differences between health states
were generally similar between the regions, and thus the
decrements associated with the various toxicity states
were comparable between the English and Scottish sam-
ples. No significant differences in utilities were observed
between older (≥ 60 years) versus younger patients,
Table 1: Mean utility values for UK general public (N = 89).
Health State Mean ± SD 95% CI (lower, upper) Toxicity disutility
Complete Response 0.91 ± 0.11 0.88, 0.93 NA
Partial Response 0.84 ± 0.14 0.81, 0.87 NA
No Change 0.78 ± 0.14 0.75, 0.82 NA
NC + 1-2 Nausea 0.73 ± 0.17 0.69, 0.76 -0.05 (0.02)
NC + 1-2 Nausea/Vomiting 0.73 ± 0.16 0.69, 0.76 -0.05 (0.02)
Second-line Treatment 0.71 ± 0.17 0.68, 0.75 NA
NC + 1-2 Diarrhea 0.70 ± 0.19 0.66, 0.74 -0.08 (0.02)
NC + 3-4 Anemia 0.69 ± 0.18 0.65, 0.72 -0.09 (0.02)
Progressive Disease 0.68 ± 0.20 0.64, 0.72 NA
NC + 3-4 Pyrexia 0.67 ± 0.17 0.63, 0.70 -0.11 (0.02)
Third-line Treatment 0.65 ± 0.22 0.60, 0.69 NA
NC + 3-4 Pneumonia 0.58 ± 0.19 0.54, 0.62 -0.20 (0.02)Beusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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between males versus females, or between higher versus
lower educational levels achieved (Levels 0-2 vs. Levels 3-
5); however, the study was not powered to detect statisti-
cally significant differences between subgroups (utilities
for education levels not tabulated) (Table 3). In addition,
preferences did not differ significantly between individu-
als who had knowledge about leukaemia versus those
who were largely unfamiliar with the disease.
Discussion
This study yielded general population utilities for a uni-
versal set of CLL health states. In future studies, these
utilities can be useful in the evaluation of CLL treatments
from the general public perspective and can be applied to
clinical trial data. Specifically, one can map the health sta-
tus of individual patients from a clinical trial to the health
s t a t es  f r o m  t h is  s t u d y ,  as s i gn  t h e  c o rr es po n d i n g  u t i l i t y
weights, and use these to compute quality-adjusted life
expectancy [23]. The use of the vignette approach, as
opposed to a generic utility assessment, made it possible
to gauge the impact of knowledge of clinical response as
well as potential CLL treatment toxicities on individual
preferences. As was expected, preferences for the health
states decreased with reduced treatment responsiveness
and with increasing grade of treatment-related toxicity.
There are similarities between the utilities obtained in
this study and those estimated by the Wessex Committee,
which were intended for use in a study of fludarabine rel-
ative to cyclophosphamide plus doxorubicin plus predni-
solone (CAP) [11]. Specifically, the Wessex Committee
estimated that the "QoL with disease" state would have a
utility of 0.81, and in this study the utility for the "no
change" health state was 0.78. The utility in this study for
"complete response" was slightly lower than that esti-
mated by Wessex for "QoL in remission" (0.91 vs. 0.96),
which may be expected given that the vignettes used in
this study included the knowledge that one has 'cancer of
the blood' regardless of the existence of symptoms.
Previously, Lloyd et al [24] and Beusterien et al [25]
used standard gamble to obtain general population utili-
ties for health states experienced in breast cancer and
advanced melanoma, respectively. Both studies found a
difference of +0.08 between the stable disease and partial
response health states. Similarly, the difference between
stable disease and partial response in this study was
+0.07. Given that, across the three studies, the only differ-
Table 2: Mean utility values in England and Scotland.
England (N = 59) Scotland (N = 30)
Health State Mean ± SD Mean ± SD Difference (p)
Complete Response 0.90 ± 0.12 0.92 ± 0.08 0.39
Partial Response 0.83 ± 0.16 0.87 ± 0.09 0.18
No Change 0.76 ± 0.15 0.83 ± 0.11 0.02
Progressive Disease 0.64 ± 0.21 0.75 ± 0.17 0.01
NC + 1-2 Nausea 0.70 ± 0.17 0.78 ± 0.16 0.04
NC + 1-2 Nausea/Vomiting 0.70 ± 0.16 0.78 ± 0.15 0.03
NC + 1-2 Diarrhea 0.68 ± 0.19 0.75 ± 0.17 0.07
NC + 3-4 Anemia 0.66 ± 0.19 0.74 ± 0.17 0.04
NC + 3-4 Pyrexia 0.64 ± 0.17 0.72 ± 0.17 0.03
NC + 3-4 Pneumonia 0.56 ± 0.20 0.63 ± 0.19 0.12
Second-line Treatment 0.68 ± 0.18 0.76 ± 0.13 0.02
Third-line Treatment 0.61 ± 0.24 0.72 ± 0.16 0.01Beusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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ence between these health states is that one is responding
to treatment, this suggests that the value of hope is equiv-
alent to +0.07 or +0.08 points on a 0-1.0 utility scale.
Szabo and colleagues used the time trade-off technique to
elicit utilities from the general population in different
countries for health states reflecting 'responding to treat-
ment' and 'not responding to treatment' for the chronic,
accelerated, and blast phases of chronic myelogenous leu-
kaemia [26]. Within each of these phases, the differences
in mean utility values between responders versus non-
responders ranged from 0.18 to 0.25. This approximates
the difference of 0.23 between complete response and
progressive disease observed in this study.
We attempted to recruit respondents according to the
distributions of age and sex of the target populations in
England and Scotland. We had a slightly lower percentage
of respondents from 18-24 years of age (8% vs. 13%) and a
slightly higher percentage of respondents who were in the
older age group (> 60 years of age) (29% vs. 26%). In addi-
tion, the study sample had attained higher levels of edu-
cation relative to the general population. Given that our
study did not find age or sex to be predictors of utility-
based preferences, it is unlikely that we would have
observed different results with a more representative
sample. Moreover, differences in respondent age or other
demographic variables have not previously been shown
to be reliable predictors of health state utilities [27].
Respondents in Scotland had slightly higher utilities
across the health states relative to those in England. The
reason for this difference in preferences is unknown, but
m a y  b e  a t t r i b u t a b l e  t o  c u l t u r a l  f a c t o r s .  O b s e r v i n g
regional differences in utility weights is consistent with
findings from previous research. For example, studies
using the EQ-5D have shown substantial inter-country
differences in utilities, including studies focusing on
patients with cancer [14,28-30]. In addition, a few direct
Table 3: Comparisons of mean utilities among subgroups.
Age Sex Knowledgeable about 
leukaemia
<60 years
(N = 63)
≥60 years
(N = 26)
Male
(N = 39)
Female
(N = 50)
Yes
(N = 23)
No
(N = 66)
Health State Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Complete Response 0.92 ± 0.09 0.88 ± 0.13 0.92 ± 0.08 0.89 ± 0.12 0.90 ± 0.13 0.91 ± 0.10
Partial Response 0.84 ± 0.14 0.84 ± 0.14 0.87 ± 0.10 0.82 ± 0.16 0.83 ± 0.17 0.85 ± 0.13
No Change 0.78 ± 0.14 0.80 ± 0.16 0.80 ± 0.13 0.77 ± 0.15 0.78 ± 0.17 0.79 ± 0.14
Progressive Disease 0.69 ± 0.19 0.65 ± 0.23 0.69 ± 0.18 0.67 ± 0.22 0.67 ± 0.23 0.68 ± 0.19
NC + 1-2 Nausea 0.72 ± 0.19 0.74 ± 0.12 0.73 ± 0.14 0.72 ± 0.19 0.76 ± 0.15 0.72 ± 0.18
NC + 1-2 Nausea/Vomiting 0.73 ± 0.16 0.73 ± 0.15 0.75 ± 0.14 0.71 ± 0.17 0.71 ± 0.15 0.73 ± 0.16
NC + 1-2 Diarrhea 0.70 ± 0.21 0.71 ± 0.14 0.70 ± 0.18 0.71 ± 0.20 0.67 ± 0.19 0.71 ± 0.19
NC + 3-4 Anemia 0.70 ± 0.19 0.65 ± 0.17 0.69 ± 0.16 0.68 ± 0.20 0.72 ± 0.21 0.67 ± 0.18
NC + 3-4 Pyrexia 0.66 ± 0.18 0.68 ± 0.15 0.66 ± 0.16 0.67 ± 0.18 0.64 ± 0.14 0.67 ± 0.18
NC + 3-4 Pneumonia 0.59 ± 0.20 0.58 ± 0.17 0.59 ± 0.19 0.58 ± 0.20 0.55 ± 0.19 0.59 ± 0.20
Second-line Treatment 0.71 ± 0.17 0.72 ± 0.16 0.74 ± 0.15 0.69 ± 0.18 0.69 ± 0.18 0.72 ± 0.16
Third-line Treatment 0.65 ± 0.23 0.63 ± 0.20 0.66 ± 0.17 0.64 ± 0.26 0.63 ± 0.24 0.65 ± 0.21
Note: No differences within subgroups statistically significant (p < 0.05; Student's t test)Beusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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estimation studies have identified systematic differences
between countries in utility weight estimates [31]. Never-
theless, despite the differences observed between Eng-
land and Scotland, the relative differences in utilities
among the health states generally were comparable,
resulting in the utility decrements associated with toxici-
ties to be about the same between regions.
We intentionally did not include a health state domain
focusing on how worried the patient would be in the
health state. Instead, we allowed the respondents to
weigh their own emotional reactions to the health states.
Preferences for health states can vary substantially across
individuals, and subjects may vary considerably in their
emotional reactions. This variability in emotional
impacts was demonstrated by Bertero et al [13], who
found that some patients with chronic leukaemia may
remain positive, and others may not cope well with the
knowledge of their cancer. Moreover, being on treatment
may have a positive emotional benefit. For example, a
large web-based survey found that CLL patients who
were previously treated or who were on active treatment
reported the same or higher scores on social/family, emo-
tional well-being, and overall QoL scales relative to
untreated patients [3]. For this CLL study, we did not
wish to impose levels of worry on each of the health
states; instead, the emotional burden associated with the
health state would be embodied in the resulting utility
values.
In addition, our study did not consider health states
with multiple toxicities. Several recent studies have
explored the estimation of utilities given this scenario.
Dale et al [32] and Fu and Kattan [33] recommend using a
minimum model, which predicts a joint-state utility as
equal to the lower of the two given single-state utilities
for an individual.
We believe we have conducted a rigorous study eliciting
utilities for CLL health states using the widely used stan-
dard gamble approach and assessing the perspective of
individuals from the general population. Utility tech-
niques mainly vary in that the values can be obtained by
individuals currently experiencing the state of interest
versus indirectly via a description of that state, called a
vignette, as was performed in this study. With respect to
the use of vignettes, the valuation might come from
patients, clinicians or the public; and the health state
description might come from qualitative research with
patients, condition-specific patient reported outcome
measures or a descriptive state classification system like
the EQ-5D or Health Utilities Index (HUI) [34]. Because
general health status measures like the EQ-5D or HUI are
generic, they may not adequately capture key psychologi-
cal impacts associated with CLL treatment, for example,
the impact of knowing that one is responding to treat-
ment. For example, decreases in quality of life during
interferon-α treatment for advanced melanoma were off-
set by the reduced risk of recurrence and mortality when
vignette-based utilities were applied [35,36]. In contrast,
IFN was only marginally better in treating melanoma
than best supportive care, when the generic EQ-5D utili-
ties were employed based on prospectively collected data
[37].
Although HTA agencies prefer that utility data from
generic measures be used in cost-effectiveness analyses,
they acknowledge that such data may not be applicable or
available. In such cases, the SMC is willing to accept data
from other sources including surveys involving "direct
measurement of utilities for appropriate disease/condi-
tion health states. This should use time trade-off or stan-
dard gamble methods of utility elicitation"[5]. NICE
acknowledges that utilities can be elicited using the stan-
dard gamble or time trade-off approach to value specially
constructed vignettes in situations where there is no ref-
erence case data or it is felt that the standardized mea-
sures do not capture all relevant aspects of the condition
or its treatment. However, they state that the problem
with this approach is that the vignettes are not directly
linked to trial evidence, raising doubts about their validity
in cost effectiveness evaluations [4].
Although the utility data in this study are not based on
a measure used in conjunction with a trial in CLL, we
believe that one should be able to map the health states or
vignettes in this study directly to those observed in such
trials. Specifically, the descriptions of treatment response
within the health states were based on the standard clini-
cal criteria used to classify treatment efficacy in CLL clin-
ical trials [20]. With respect to the toxicities that can
occur, we believe that application of utilities obtained for
t h e  t o x i c i t y  v i g n e t t e s  i n  t h i s  s t u d y  m a y  e v e n  b e  m o r e
accurate than those based on a generic measure used in a
trial, particularly because it may be difficult to administer
a patient reported outcomes measure in a timely way in
conjunction with such events. Given the standardized
descriptions used for the health states in this study, we
believe that they could mirror Markov states to which
clinical trial patients could be assigned.
Conclusions
The study reports general population health state utilities
from the UK, including both England and Scotland, for a
universal set of CLL states, including potential clinical
outcomes and toxicities associated with various treat-
ments. This study employed a rigorous process for the
development of standardized health states that incorpo-
rated both intended treatment responses and unintended
events. The utilities generated in this study can be applied
in future cost-utility analyses of treatments for CLL.Beusterien et al. Health and Quality of Life Outcomes 2010, 8:50
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